Role of Influenza B virus in hepatic steatosis and mitochondrial abnormalities in a mouse model of reye syndrome

Hepatology ◽  
1991 ◽  
Vol 13 (1) ◽  
pp. 96-103 ◽  
Author(s):  
Kathleen B. Schwarz ◽  
Saroj Larroya ◽  
Carole Vogler ◽  
C. Jeffrey Sippel ◽  
Sharon Homan ◽  
...  
1994 ◽  
Vol 68 (2) ◽  
pp. 1250-1254 ◽  
Author(s):  
F Yamamoto-Goshima ◽  
K Maeno ◽  
T Morishita ◽  
M Ueda ◽  
Y Fujita ◽  
...  

1982 ◽  
Vol 59 (1) ◽  
pp. 183-186 ◽  
Author(s):  
M. Shibata ◽  
K. Maeno ◽  
T. Tsurumi ◽  
H. Aoki ◽  
Y. Nishiyama ◽  
...  

2019 ◽  
Vol 74 (5) ◽  
pp. 1333-1341 ◽  
Author(s):  
Philippe Noriel Q Pascua ◽  
Bindumadhav M Marathe ◽  
Peter Vogel ◽  
Richard J Webby ◽  
Elena A Govorkova

2019 ◽  
Vol 93 (12) ◽  
Author(s):  
Weina Sun ◽  
Ericka Kirkpatrick ◽  
Megan Ermler ◽  
Raffael Nachbagauer ◽  
Felix Broecker ◽  
...  

ABSTRACTInfluenza B viruses cause seasonal epidemics and are a considerable burden to public health. However, protection by current seasonal vaccines is suboptimal due to the antigenic changes of the circulating strains. In this study, we report a novel universal influenza B virus vaccination strategy based on “mosaic” hemagglutinins. We generated mosaic B hemagglutinins by replacing the major antigenic sites of the type B hemagglutinin with corresponding sequences from exotic influenza A hemagglutinins and expressed them as soluble trimeric proteins. Sequential vaccination with recombinant mosaic B hemagglutinin proteins conferred cross-protection against both homologous and heterologous influenza B virus strains in the mouse model. Of note, we rescued recombinant influenza B viruses expressing mosaic B hemagglutinins, which could serve as the basis for a universal influenza B virus vaccine.IMPORTANCEThis work reports a universal influenza B virus vaccination strategy based on focusing antibody responses to conserved head and stalk epitopes of the hemagglutinin. Recombinant mosaic influenza B hemagglutinin proteins and recombinant viruses have been generated as novel vaccine candidates. This vaccine strategy provided broad cross-protection in the mouse model. Our findings will inform and drive development toward a more effective influenza B virus vaccine.


2017 ◽  
Vol 148 ◽  
pp. 20-31 ◽  
Author(s):  
Bindumadhav M. Marathe ◽  
Heba H. Mostafa ◽  
Peter Vogel ◽  
Philippe Noriel Q. Pascua ◽  
Jeremy C. Jones ◽  
...  

2020 ◽  
Vol 94 (23) ◽  
Author(s):  
Ericka Kirkpatrick ◽  
Carole Henry ◽  
Meagan McMahon ◽  
Kaijun Jiang ◽  
Shirin Strohmeier ◽  
...  

ABSTRACT Humoral immune responses to influenza virus vaccines in elderly individuals are poorly adapted toward new antigenically drifted influenza virus strains. Instead, older individuals respond in an original antigenic sin fashion and produce much more cross-reactive but less potent antibodies. Here, we investigated four influenza B virus hemagglutinin (HA) head specific, hemagglutination inhibition-inactive monoclonal antibodies (MAbs) from elderly individuals. We found that they were broadly reactive within the B/Victoria/2/1987-like lineage, and two were highly cross-reactive with B/Yamagata/16/1988-like lineage viruses. The MAbs were found to be neutralizing, to utilize Fc effector functions, and to be protective against lethal viral challenge in a mouse model. In order to identify residues on the influenza B virus hemagglutinin interacting with the MAbs, we generated escape mutant viruses. Interestingly, escape from these MAbs led to numerous HA mutations within the head domain, including in the defined antigenic sites. We observed that each individual escape mutant virus was able to avoid neutralization by its respective MAb along with other MAbs in the panel, although in many cases binding activity was maintained. Point mutant viruses indicated that K90 is critical for the neutralization of two MAbs, while escape from the other two MAbs required a combination of mutations in the hemagglutinin. Three of four escape mutant viruses had increased lethality in the DBA2/J mouse model. Our work indicates that these cross-reactive antibodies have the potential to cause antigenic drift in the viral population by driving mutations that increase virus fitness. However, binding activity and cross-neutralization were maintained by a majority of antibodies in the panel, suggesting that this drift may not lead to escape from antibody-mediated protection. IMPORTANCE Understanding the immune response that older individuals mount to influenza virus vaccination and infection is critical in order to design better vaccines for this age group. Here, we show that older individuals make broadly neutralizing antibodies that have no hemagglutination-inhibiting activity and are less potent than strain-specific antibodies. These antibodies could drive viral escape from neutralization but did not result in escape from binding. Given their different mechanisms of action, they might retain protective activity even against escape variants.


1999 ◽  
Vol 80 (11) ◽  
pp. 2969-2976 ◽  
Author(s):  
C. Luo ◽  
E. Nobusawa ◽  
K. Nakajima

We analysed the role of neuraminidase (NA) on haemadsorption by the haemagglutinin (HA) protein of influenza B virus. The influenza B virus mutant ts-7 has a temperature-sensitive mutation in the NA protein. At high temperature, cells infected with this virus did not exhibit haemadsorption activity, but the addition of bacterial neuraminidase (bNA) restored haemadsorption activity. COS cells transfected with HA cDNAs of B/Kanagawa/73 or B/Lee/40 virus showed no evidence of haemadsorption. However, with the addition of bNA or co- transfection with NA cDNA of the B/Lee/40 virus, haemadsorption was observed. Experiments with point-mutated HA cDNAs of B/Lee/40 virus showed that two N-acetyl glycosylation sites at amino acid residues 160 and 217 were responsible for the inability of the HA protein to adsorb to erythrocytes. These results indicated that haemadsorption by the HA protein of influenza B virus required the involvement of NA. Because the NA inhibitor Zanamivir was reported not to penetrate cells, we investigated the action of this inhibitor and found that Zanamivir inhibited haemadsorption on MDCK cells infected with B/Kanagawa/73 or B/Lee/40 virus. After removing Zanamivir by washing, the addition of bNA restored the haemadsorption activity on the infected cells. Scanning electron microscopy indicated that at 0·4 μM Zanamivir, HA protein did not adsorb to erythrocytes but retained the ability to aggregate virions. However, at 4 μM Zanamivir, distinct virion formation could not be observed.


Sign in / Sign up

Export Citation Format

Share Document